KI
AVIR icon

Kapitalo Investimentos’s Atea Pharmaceuticals AVIR Stock Holding History

Kapitalo Investimentos’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,500
Closed -$41.9K – 491
2023
Q1 		$41.9K Hold
12,500
– – 0.01% 405
2022
Q4 		$60.1K Hold
12,500
– – 0.05% 122
2022
Q3 		$71.1K Hold
12,500
– – 0.03% 34
2022
Q2 		$88.8K Hold
12,500
– – 0.06% 33
2022
Q1 		$90.3K Hold
12,500
– – 0.1% 29
2021
Q4 		$112K Sell
12,500
-6,000
-32% -$93.5K 0.13% 30
2021
Q3 		$649K Buy
+18,500
New +$513K 0.34% 31

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kapitalo Investimentos's AVIR Position: Q2 2023 in Review

Kapitalo Investimentos sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 12,500 shares — an estimated $41.9K sold.

Kapitalo Investimentos first reported a position in AVIR in Q3 2021 and held it in 7 quarters. The position peaked at $649K in Q3 2021. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

  • Kapitalo Investimentos reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Kapitalo Investimentos sold 12,500 Atea Pharmaceuticals shares in Q2 2023, an estimated $41.9K.
  • Kapitalo Investimentos first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • Kapitalo Investimentos's Atea Pharmaceuticals position peaked at $649K in Q3 2021.
  • 133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Kapitalo Investimentos's 13F filing for Q2 2023, filed 29 Mar 2024.